EZH2 is a clinically relevant lymphoma target with opportunity in immune-epigenetic combinations.

MDM2 is niche but compelling in liposarcoma, where focused evidence matters more than raw trial volume.

FGFR3 is a focused urothelial carcinoma target with biomarker-driven opportunity.

VEGFR2 is validated in RCC, but new value comes from regimen and sequencing design.

BCL2 is validated in CLL; modern value depends on combination, MRD, and sequencing strategy.

BTK is a deeply validated CLL target with intense competition and meaningful white space in resistance, safety, and fixed-duration combinations.

JAK2 is a validated myelofibrosis target where differentiation depends on clinically meaningful subgroups and endpoints.

FLT3 is a highly validated AML target with active opportunity in combinations, maintenance, and resistance-focused development.

IDH1 is a focused, clinically validated AML target with remaining opportunity in combination and sequencing strategy.

NTRK1 is attractive in fusion-positive solid tumors, but evidence quality depends on precise biomarker filtering.

CDK4 is a highly validated breast cancer target with remaining opportunity in selectivity, sequencing, and endocrine-combination strategy.

PARP1 is a validated ovarian cancer target, with new opportunity concentrated in biomarker precision and combination strategy.